-
公开(公告)号：US20170166578A1
公开(公告)日：2017-06-15
申请号：US15039607
申请日：2014-12-17
Applicant: Merck Sharp & Dohme Corp.
Inventor： William K. Hagmann , Bing Li , Jason W. Szewczyk , Bowei Wang , Dann Parker , Timothy Blizzard , Hubert Josien , Purakkattle Biju , Harry Chobanian , Candido Gude , Ravi P. Nargund , Barbara Pio , Qun Dang , Linus S. Lin , Bin Hu , Mingxiang Cui , Zhengxia Chen , Meibi Dai , Zaihong Zhang , Ying Lv , Lili Tian
IPC: C07D493/04 , C07D213/64 , A61K31/44 , C07D409/12 , A61K31/4436 , C07D401/04 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D405/12 , A61K31/4433 , C07D401/12 , A61K31/4439 , A61K31/443 , C07D239/34 , A61K31/505 , C07D451/06 , A61K31/46 , C07D221/20 , A61K31/438 , A61K31/506 , C07D213/74 , C07D417/04 , A61K45/06
CPC classification number: C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US09834563B2
公开(公告)日：2017-12-05
申请号：US15039607
申请日：2014-12-17
Applicant: Merck Sharp & Dohme Corp.
Inventor： William K. Hagmann , Bing Li , Jason W. Szewczyk , Bowei Wang , Dann Parker , Timothy Blizzard , Hubert Josien , Purakkattle Biju , Harry Chobanian , Candido Gude , Ravi P. Nargund , Barbara Pio , Qun Dang , Linus S. Lin , Bin Hu , Mingxiang Cui , Zhengxia Chen , Meibi Dai , Zaihong Zhang , Ying Lv , Lili Tian
IPC: A61K31/506 , C07D493/04 , A61K45/06 , C07D213/64 , A61K31/44 , C07D409/12 , A61K31/4436 , C07D401/04 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D405/12 , A61K31/4433 , C07D401/12 , A61K31/4439 , A61K31/443 , C07D239/34 , A61K31/505 , C07D451/06 , A61K31/46 , C07D221/20 , A61K31/438 , C07D213/74 , C07D417/04
CPC classification number: C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号：US09018224B2
公开(公告)日：2015-04-28
申请号：US14358241
申请日：2012-11-09
Applicant: Merck Sharp & Dohme Corp.
Inventor： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC: A01N43/54 , A61K31/505 , C07D513/04 , C07D401/14 , C07D405/14 , C07D413/14 , C07D401/04 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04 , C07D239/42 , C07D403/12 , C07D403/14 , C07D405/12 , C07D409/12
CPC classification number: C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included.
Abstract translation: 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法。
-
公开(公告)号：US20140329798A1
公开(公告)日：2014-11-06
申请号：US14358241
申请日：2012-11-09
Applicant: Merck Sharp & Dohme Corp.
Inventor： Scott Edmondson , Zhiyong Hu , Ping Liu , Gregori J. Morriello , Jason W. Szewczyk , Bowei Wang , Liping Wang , Harold B. Wood , Cheng Zhu , Yuping Zhu , Zhiqiang Guo
IPC: C07D513/04 , C07D239/42 , C07D405/12 , C07D409/12 , C07D498/04 , C07D487/04 , C07D403/14 , C07D401/14 , C07D403/12 , C07D471/04
CPC classification number: C07D513/04 , C07D239/42 , C07D401/04 , C07D401/14 , C07D403/12 , C07D403/14 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07D495/04 , C07D498/04
Abstract: Substituted cyclopropyl compounds of the formula (I): and pharmaceutically acceptable salts thereof are disclosed as useful for treating or preventing type 2 diabetes and similar conditions. The compounds are useful as agonists of the G-protein coupled receptor GPR-119. Pharmaceutical compositions and methods of treatment are also included
Abstract translation: 披露式（I）的取代的环丙基化合物及其药学上可接受的盐可用于治疗或预防2型糖尿病和类似病状。 该化合物可用作G蛋白偶联受体GPR-119的激动剂。 还包括药物组合物和治疗方法
-
-
-
Search Results
4
records
(took 0.019 seconds)
